Biocytogen 百奥赛图
7 significant filings since 29 May 2026: 1 on litigation, 2 on guarantee or financial assistance and 2 on new listing, and 2 other kinds. The latest, on 7 Aug 2026: 百奥赛图（北京）医药科技股份有限公司2026年半年度业绩预告的自愿性披露公告. On 7 Aug 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 391.87% to 412.71% from the same period a year earlier.
自 29 May 2026 起有 7 份重大公告：litigation 1 份、guarantee or financial assistance 2 份、new listing 2 份，另有 2 类。最新一份（7 Aug 2026）：百奥赛图（北京）医药科技股份有限公司2026年半年度业绩预告的自愿性披露公告。7 Aug 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 391.87% 至 412.71%。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 1 broker | 1 broker |
| 7 days ago | 1 broker | 1 broker |
| 30 days ago | 1 broker | 1 broker |
| 60 days ago | 2 brokers | 2 brokers |
| 90 days ago | 2 brokers | 2 brokers |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 1 ▼ 0 = 0 | ▲ 1 ▼ 0 = 0 |
| Last 90 days | ▲ 1 ▼ 0 = 0 | ▲ 1 ▼ 0 = 0 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 1.